- Home
- GRNT vs OVID Comparison
GRNT vs OVID Comparison
Compare GRNT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | OVID |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.7M | 522.6M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GRNT | OVID |
|---|---|---|
| Price | $4.54 | $2.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $6.00 | $4.60 |
| AVG Volume (30 Days) | 827.6K | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | ★ 28.57 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $450,306,000.00 | $7,252,000.00 |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 18.49 | ★ 1181.27 |
| 52 Week Low | $4.18 | $0.48 |
| 52 Week High | $6.15 | $3.11 |
Technical Indicators
Market Signals| Indicator | GRNT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 43.55 |
| Support Level | $4.23 | $2.33 |
| Resistance Level | $4.79 | $2.38 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 7.92 | 19.13 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.